Related references
Note: Only part of the references are listed.Sources to variability in circulating human miRNA signatures
Andreas Keller et al.
RNA BIOLOGY (2017)
The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab
Ondrej Fiala et al.
TUMOR BIOLOGY (2017)
miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4
Lei Ding et al.
ONCOLOGY LETTERS (2017)
MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer
Yiying Wu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
MicroRNA-17∼92 inhibits colorectal cancer progression by targeting angiogenesis
Huabin Ma et al.
CANCER LETTERS (2016)
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival
Kosuke Mima et al.
CLINICAL CANCER RESEARCH (2016)
Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers
Tsutomu Kawaguchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Emerging role of microRNA-21 in colorectal cancer
Jun Zhao et al.
CANCER BIOMARKERS (2015)
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
Daniel A. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
LPS Induced miR-181a Promotes Pancreatic Cancer Cell Migration via Targeting PTEN and MAP2K4
Jianhui Liu et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
Regorafenib: A Review of Its Use in Previously Treated Patients with Progressive Metastatic Colorectal Cancer
Natalie J. Carter
DRUGS & AGING (2014)
Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer
Yuji Toiyama et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Plasma MiR-21 A Potential Diagnostic Marker of Colorectal Cancer
Ziad Kanaan et al.
ANNALS OF SURGERY (2012)
MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGF beta R2) in colon cancer cells
Yingjie Yu et al.
CARCINOGENESIS (2012)
Circulating miR-34a levels are reduced in colorectal cancer
M. Nugent et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer
Qifeng Wang et al.
PLOS ONE (2012)
Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer
K. Liu et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis
Hanyin Cheng et al.
PLOS ONE (2011)
MiR-21 Induced Angiogenesis through AKT and ERK Activation and HIF-1α Expression
Ling-Zhi Liu et al.
PLOS ONE (2011)
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
Zhaohui Huang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression
Xing-xiang Pu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Maria Angelica Cortez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening
E. K. O. Ng et al.
GUT (2009)
Supervised learning with decision tree-based methods in computational and systems biology
Pierre Geurts et al.
MOLECULAR BIOSYSTEMS (2009)
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
I. A. Asangani et al.
ONCOGENE (2008)
Share Paper
